Hoersholm, Denmark, April 12th, 2017 – Medical Prognosis Institute A/S (MPI.ST) (Denmark and Phoenix, AZ, USA) today announced that an abstract has been accepted for presentation at this year’s ASCO (American Society of Clinical Oncology). The title of the abstract is “Retrospective-prospective blinded evaluation predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort”. The poster will be presented on the 4th of June at the annual ASCO conference in Chicago Illinois taking place from June 2-6 2017.
The poster will be presented on the poster session Breast Cancer-Metastatic
on the 4th of June 2017 at 8:00 AM-11:30 AM local time/ 15:00-18:30 CET
The abstract will be released by ASCO
on May 17, 2017, at 5:00 PM EDT/ 23:00 CET on abstracts.asco.org.
ASCO, American Society of Clinical Oncology, ANNUAL MEETING. McCormick Place, Chicago, Illinois, USA.
Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. The ASCO Annual Meeting is considered the premiere international forum for the presentation of scientific research and state-of-the-art education in clinical oncology. The five-day event attracts 30,000 attendees from around the world. Clinical trial results and updates presented at ASCO’s Annual Meeting represent the significant progress made each year in the fight against cancer.
On the 24th of January 2017 MPI published information on data from more than 800 patients with metastatic breast cancer: Data for epirubicin, fulvestrant, anastrazole and exemestan demonstrated with statistical significant values that the PRP could predict whether the individual patients responded on the treatment with the mentioned drugs or not. As there is a high number of active anticancer agents for Breast Cancer and this approach has been very fruitful OV and MPI will continue to broaden the database and the data mining to increase the number of products where our technology can bring value to the choice of therapy.
“Anthracyclines like epirubicin are corner stones in the treatment of several cancers such as breast cancer, lymphomas and sarcomas. The potential value of the DRP(TM)’s ability to correctly predict those patients who will benefit from these treatments is huge. We are building the Patient Response Predictor – PRP(TM) starting with breast cancer and these epirubicin prediction data will play an important role. In addition to this successful data are important for the matching of breast cancer patients with the liposomal doxorubicin product 2X-111 developed by 2X Oncology Inc. currently 92% owned by Oncology Venture”, says Adjunct Professor Peter Buhl Jensen, M.D., CEO of MPI. “. I look forward to the presentation of the epirubicin DRP(TM) data at the annual ASCO – the largest event for oncologists and anticancer drug developers,” Peter Buhl Jensen further commented.
About MPI’s multiple biomarker called Drug Response Predictor – DRP(TM)
MPI’s DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anti-cancer drug. In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP(TM) is a Big Data tool based on messenger RNA.
The DRP(TM) platform can be used in all cancer types, and has been patented for more than 70 anti-cancer drugs in the US.
About MPI
Medical Prognosis Institute a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI’s exceptional opportunity to personalize cancer treatment – begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI’s DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,100 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.
For further information, please contact:
CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.D. Ulla Hald Buhl, IR & Communication
E-mail: [email protected] E-mail: [email protected]
Telephone: +45 21 60 89 22 Telephone: +45 21 70 10 49
